Literature DB >> 11732940

Malignant ascites: new concepts in pathophysiology, diagnosis, and management.

N Aslam1, C R Marino.   

Abstract

Malignant ascites is a manifestation of advanced malignant disease that is associated with significant morbidity. Mainstays of treatment include diuretics and recurrent large volume paracentesis. Although lymphatic obstruction has been considered the major pathophysiologic mechanism behind its formation, recent evidence suggests that immune modulators, vascular permeability factors, and metalloproteinases are contributing significantly to the process. These new observations offer the opportunity for development of new, more targeted therapies for the treatment of malignant ascites. This article uses a clinical case to highlight the problem, then reviews these new concepts in the pathophysiology of malignant ascites formation. The diagnosis and management of this challenging medical problem are subsequently discussed, with emphasis on how these new pathophysiologic insights are being applied to the development of novel therapies that may soon change how we manage this troubling clinical condition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732940     DOI: 10.1001/archinte.161.22.2733

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

1.  Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites.

Authors:  Hong Zhang; Feng Li; Qun Wei; Yu-Fei Zhu
Journal:  Med Oncol       Date:  2010-11-02       Impact factor: 3.064

2.  Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer.

Authors:  Daniel T Rein; Anne Kathrin Volkmer; Jens Volkmer; Ines M Beyer; Wolfgang Janni; Markus C Fleisch; Anne Kathrin Welter; Dirk Bauerschlag; Thomas Schöndorf; Martina Breidenbach
Journal:  Oncol Lett       Date:  2012-01-03       Impact factor: 2.967

3.  The clinical significance of vascular endothelial growth factor in malignant ascites.

Authors:  Na Zhan; Wei-Guo Dong; Jing Wang
Journal:  Tumour Biol       Date:  2015-10-13

4.  Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.

Authors:  Daye Cheng; Bin Liang; Hong Kong
Journal:  Med Oncol       Date:  2011-05-10       Impact factor: 3.064

5.  Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites.

Authors:  Nian Fang; Hui-Qing Zhang; Bo He; Mei Xie; Shan Lu; Yi-Ye Wan; Nong-Rong Wang
Journal:  Tumour Biol       Date:  2013-11-27

6.  A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Hatem Elalfy; Tarek Fouad Sheta; Mahmoud Awad; Mostafa Abdelsalam; Rania Elhelaly; Rasha Elzehery; Nawal S Gouda; Waleed Eldars
Journal:  J Gastrointest Cancer       Date:  2017-03

7.  Detection of type IV collagenase activity in malignant ascites.

Authors:  Xiao-Min Sun; Wei-Guo Dong; Bao-Ping Yu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

8.  Role of VEGF and CD44v6 in differentiating benign from malignant ascites.

Authors:  Wei-Guo Dong; Xiao-Min Sun; Bao-Ping Yu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

9.  Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.

Authors:  Angel Mier Hicks; Joanne Chou; Marinela Capanu; Maeve A Lowery; Kenneth H Yu; Eileen M O'Reilly
Journal:  Clin Colorectal Cancer       Date:  2016-05-07       Impact factor: 4.481

10.  Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.

Authors:  Hae Kyung Lee; Hiun Suk Chae; Jin Soo Kim; Hyung Keun Kim; Young Seok Cho; Sang Young Rho; Jin-Hyoung Kang; Seok Goo Cho; Hong Seok Jang; Kyungja Han
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.